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Molecular characterization of apoptosis induced by
CARF silencing in human cancer cells
CT Cheung1, R Singh1, AR Yoon2, MK Hasan1,3, T Yaguchi1, SC Kaul*,1, CO Yun*,2 and R Wadhwa*,1
Collaborator of ARF (CARF) was cloned as an ARF-interacting protein and shown to regulate the p53–p21WAF1–HDM2 pathway,
which is central to tumor suppression via senescence and apoptosis. We had previously reported that CARF inhibition in cancer
cells led to polyploidy and caspase-dependent apoptosis, however, the mechanisms governing this phenomenon remained
unknown. Thus, we examined various cell death and survival pathways including the mitochondrial stress, ataxia telangiectasia
mutated (ATM)–ATR, Ras–MAP kinase and retinoblastoma cascades. We found that CARF is a pleiotropic regulator with
widespread effects; its suppression affected all investigated pathways. Most remarkably, it protected the cells against
genotoxicity; CARF knockdown elicited DNA damage response as evidenced by increased levels of phosphorylated ATM and
cH2AX, leading to induction of mitotic arrest and eventual apoptosis. We also show that the CARF-silencing-induced apoptosis
in vitro translates to in vivo. In a human tumor xenograft mouse model, treatment of developing tumors with short hairpin RNA
(shRNA) against CARF via an adenovirus carrier induced complete suppression of tumor growth, suggesting that CARF shRNA
is a strong candidate for an anticancer reagent. We demonstrate that CARF has a vital role in genome preservation and tumor
suppression and CARF siRNA is an effective novel cancer therapeutic agent.
Cell Death and Differentiation (2011) 18, 589–601; doi:10.1038/cdd.2010.129; published online 5 November 2010
Tumor suppression largely function via the p53–p21WAF1–HDM2
pathway for promotion of cell growth arrest, senescence, or
programmed cell death to eliminate damaged cells or to halt
neoplastic activities.1 We had previously isolated an alter-
native reading frame (ARF)-binding protein, Collaborator of
ARF (CARF), which functions in regulation of p53-mediated
tumor suppression.2 Further, we discovered that the CARF
protein is a vital regulator of p53-dependent senescence and
apoptosis, and the determinant of cell fate is reliant on the
dosage or level of CARF.3 CARF is critical for cell cycle
progression, and CARF-compromised cells display hallmarks
of mitotic catastrophe (MC) including hypercondensed
chromatin, polyploidy, as well as deranged spindle fiber and
centrosome assemblies. In this study, we sought to elucidate
the mechanisms responsible for CARF-suppression-induced
cell death and its in vivo effects.
MC is characterized by mitotic arrest accompanied by
increases in histone H3, cyclin B1 and cyclin-dependent
kinase 1 and deregulation of the cell cycle checkpoints,
culminating into cell death.4 Although a clear definition of MC
is lacking, it is widely considered as a mode of apoptosis
owing to accompanying changes in mitochondrial membrane
potential and caspase activation.5 Regulation of the cell
survival and death processes has been largely attributed to
p53-dependent and p53-independent pathways involving
retinoblastoma (RB), E2F1, p21WAF1, Ras–mitogen-activated
protein kinases (MAPK) and ataxia telangiectasia mutated
(ATM)/ATM- and RAD3-related (ATR) functions.6–9 The latter
serve as prime mediators of the DNA damage response,
instigating apoptosis through Ras–MAPK, RB–E2F1 and
ARF–p53–p21WAF1 or mitotic DNA damage checkpoint
mediated by the BRCA1 and CHK1 pathways.10–14
In the present study, we report that the suppression
of CARF induces MC accompanied by activation of the
mitochondrial stress and caspase-dependent pathways via
induction of DNA damage and disruption of the cell cycle
checkpoint regulation, culminating into apoptosis of cancer
cells. Furthermore, in an in vivo tumor model using adeno-
oncolytic virus armed with CARF siRNA, complete suppres-
sion of tumors was observed, suggesting that CARF siRNA is
a strong candidate for antitumor therapy.
Results
CARF-silencing-induced cell death is p53-independent
and involves the mitochondrial stress pathway. We
previously showed that the suppression of CARF
compromised p53 function causing reduction in the level of
p21WAF1 expression.15 However, it remained unclear whether
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functional compromise of p53 was critically involved in the cell
death phenotype. CARF-silencing induced cell death in HeLa
(compromised p53 function owing to the presence of
human papilloma virus; Figure 1a), DLD-1 and C33A (mutant
p53; data not shown), as well as in HCT116 p53/ cells
(Figure 1b). These data indicated that p53 is not a crucial
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factor for CARF-silencing-induced cell death and hence, other
factors and pathways warranted further investigations.
We utilized CARF siRNA in U2OS (functional wild-type p53)
and HeLa cells and examined the expression of cyclin B1 and
histone H3 (crucial regulators of mitosis and major markers
of MC).5 As shown in Figure 1c, cyclin B1 and histone H3 were
increased following CARF suppression. In contrast to the
predominantly pancytoplasmic cyclin B1 in normal cycling
cells, cyclin B1 accumulated in the nucleus of CARF-
compromised cells (Figure1d, arrows), which exhibited
compact and condensed chromosomes as in prophase and
metaphase cells, suggesting that the CARF-compromised
cells were arrested at mitosis owing to inhibition of cyclin B1
degradation that normally occurs for mitotic exit and may have
thus undergone MC before cell death.16,17 The fact that there
was no change in FADD expression after CARF suppression
(Figure 1e) was suggestive that the CARF suppression
was not recognized as an external stress. On the other
hand, specific activation of mediators of the internal stress
response-apoptosis pathway, such as upregulation of
Bak (pro-apoptotic protein) and downregulation of Bcl-2
(antiapoptotic protein), were observed (Figure 1e) suggesting
that CARF suppression was recognized as an internal stress
response leading to cleavage and activation of caspases 2, 3,
7 and 9. The data suggested that the CARF-silencing-induced
apoptosis was mediated predominantly by the mitochondrial–
internal stress pathway.18,19 To elucidate the mechanistic
processes involved in this phenomenon, we next investigated
three major cell stress pathways, including the Ras–MAPK,
RB–E2F1 and ATM–ATR–CHK cascades, involved in
p53-independent growth arrest and cell death (Figure 1f).
Ras pathways are activated, but not essential in
CARF-silencing-induced cell death. We earlier showed
that normal cells undergo stress-induced premature
senescence by overexpression of CARF, which is mediated
by upregulation of Ras, a small GTPase proto-oncogene
activated by receptor tyrosine kinases that regulates cell
survival and death pathways.3 We first sought to determine
whether the Ras-MAPK pathway is involved in CARF-
silencing-induced apoptosis. As shown in Figure 2a, CARF
suppression led to downregulation of Ras and inactivation of
its downstream effector MAP kinases, extracellular regulated
kinases (ERK)1/2; the level of phosphorylated ERK1/2 was
decreased in CARF-compromised cells. In order to address
whether this pathway is critical for CARF-silencing-induced
apoptosis, we investigated whether exogenous expression of
ERK1/2 could reverse the apoptosis caused by CARF
inhibition. As ERK1 and ERK2 are functionally comparable
in the regulation of apoptosis, only ERK1-overexpressing
U2OS cells were generated. Cells expressing control GFP
and GFP-ERK1 proteins were compared for CARF-silencing-
induced apoptosis (Figure 2b). As shown in Figure 2c and d,
cell viability and cleavage of caspase 3 were observed
at a similar level in control and ERK1-overexpressing cells,
implying that downregulation of the Ras-MAPK signaling was
not essential in cell death induced by CARF-suppression.
This was further verified by an independent experiment in
which we suppressed CARF in HT1080 cells, which harbor
Ras overexpression and constitutively active MAPK
signaling. HT1080 cells showed a high rate of sponta-
neous apoptosis, as supported by caspase 3 cleavage, but
suppression of CARF did not cause any further increase in
cell death (Figure 2e).
In order to further investigate and verify the crucial
involvement of the MAPK cascade, we recruited MAPK
inhibitors. As shown in Figure 2f, HT1080 cells transfected
with CARF siRNA were treated with PD98059, a potent
MEK1/2 inhibitor. Cell viability of control and treated cells was
the same indicating that the MAPK pathway was not critically
involved in CARF-suppression induced apoptosis. Treatment
with another MEK1/2 inhibitor, U0126, generated similar
results (data not shown).
To determine whether the suppression of CARF
also involves the other Ras-regulated pathways mediated
by PI3K–Akt and p38MAPK, we treated cells transfected with
CARF siRNA cells with wortmannin (PI3K inhibitor) or
SB203580 (p38MAPK inhibitor). Cell death was induced in
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Figure 1 Cell death induced by CARF suppression occurs after mitotic arrest
through the mitochondrial stress and caspase-dependent pathway. TUNEL staining
of HeLa cells transfected with CARF-targeting siRNA shows increased cell death
following CARF suppression (a). Syngeneic p53 þ /þ and p53/ HCT116 cells
showed comparable apoptosis (decreased cell viability, left and increase in caspase
3 activity, right) after CARF suppression (b). CARF-compromised cells underwent
mitotic arrest as evidenced by accumulation of cyclin B1 and histone H3 with
densitometric quantitation of representative blots from at least three experiments, in
which the CARF-suppressed group is shown as fold change over control, which was
set as 1 (c). Immunofluorescence shows that cells with reduced CARF levels
had increased cyclin B1 nuclear accumulation, as shown by the arrows (d). CARF-
compromised HeLa cells were subjected to immunoblotting analyses for proteins
constituting the mitochondrial stress and caspase pathways (e). Actin and a-Tubulin
were used as loading controls. Graphs are represented as average mean±S.D.
(f) Schematic diagram of the hypothetical pathways that lead to cell death following
CARF inhibition. We considered that apoptosis induced by CARF suppression might
activate multiple pathways, including the ATM/ATR/CHK1/CHK2, Ras-MAPK
and/or RB/E2F1 networks
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an identical manner after both treatments in the CARF-
compromised cells (Figure 2g), indicating that the various
Ras pathways are not critically involved in this cell
death process.
RB–E2F1 pathway is involved, but not required for CARF
silencing-induced cell death. We had earlier shown that
premature senescence induced in normal cells by CARF
overexpression was associated with increase in RB.3 As the
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Figure 2 The Ras-associated pathways are not required for cell death induced by CARF suppression. Ras, total ERK and phosphoERK1/2 were evaluated by
immunoblotting in CARF-compromised U2OS cells with densitometric quantitation of representative blots from at least three experiments (a). U2OS cells with overexpression
of GFP-ERK1 was transfected with CARF siRNA (b), and cell viability was measured by trypan blue exclusion assay (c) and immunoblotting for procaspase 3 with
densitometric quantitation of representative blots from at least three experiments (d). CARF-compromised HT1080 cells were analyzed for total ERK, phosphoERK1/2, CHK1
and caspase cleavage by immunoblotting (e). ERK1/2 was inhibited in CARF-suppressed HT1080 cells by treatment with PD98059, and cell viability was measured using the
trypan blue exclusion method (f). p38MAPK and PI3K were inhibited in CARF-compromised U2OS cells by treatment with SB203580 and wortmannin, respectively, and cell
viability was measured as above (g). Actin and a-Tubulin were used as loading controls. Densitometric quantitations were performed wherein, the CARF-suppressed group
is shown as fold change over control siRNA, which was set as 1. Graphs are represented as average mean±S.D. Cell viability was measured as pecentage of surviving
CARF-targeted cells to control siRNA-transfected cells, which was considered as 100%
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Figure 3 Cell death induced by CARF inhibition is not critically dependent on RB. Total RB, phosphorylated RB, E2F1 and caspase 3 were analyzed by immunoblotting in
CARF-compromised U2OS cells with densitometric quantitation of representative blots from at least three experiments, in which the CARF-suppressed group is shown as fold
change over control, which was set as 1 (a). Saos-2 cells were transfected with CARF-targeting siRNA and cell viability was measured by the trypan blue exclusion assay (b).
CARF, E2F1, p21CIP1/WAF1, caspase 3 and CHK1 were evaluated by western blotting in CARF-compromised Saos-2 cells (c). Control and RB-restored Saos-2 cells were
subjected to CARF inhibition and immunoblotting for CARF, HA tag, RB, CHK1 and caspases 3, 7 and 9 was performed (d). Cell viability of control and RB-restored Saos-2
cells following CARF suppression was also conducted (e). Actin and a-Tubulin were used as loading controls. Graphs are represented as average mean±S.D. Cell viability
was measured as percentage of surviving CARF-targeted cells to control siRNA-transfected cells, which was considered as 100%
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RB–E2F1 pathway modulates apoptosis by p53-independent
mechanisms, we investigated if RB has a role in the CARF
cell death pathway. As shown in Figure 3a, although total RB
protein was not significantly altered after CARF suppression,
there were proportional reductions in all phosphorylated
forms of RB, including serines 780, 795 and 807/811 and in
E2F1 (Figure 3a), signifying growth arrest, which may have
ultimately resulted in apoptosis via cleavage of caspase 3.
To determine whether RB is essential for CARF-silencing-
induced cell death, we suppressed CARF in RB/ Saos-2
cells. In contrast to U2OS and HeLa, Saos-2 cells were
resistant to CARF-silencing-induced cell death (Figure 3b)
and did not show caspase 3 cleavage or changes in E2F1,
p21WAF1 and CHK1 expression (Figure 3c). CARF inhibition
was thus, conducted in RB-restored Saos-2 cells to deter-
mine whether the cell death phenotype could be reversed.
As shown in Figure 3d, HA-tagged RB was restored in
Saos-2 cells, however, after CARF suppression, caspase
activation was still comparable to non-restored CARF-
compromised cells, and no apoptosis was observed
(Figure 3d and e). Thus, although CARF siRNA-transfected
cells were compromised for RB phosphorylation leading to
growth arrest, it was not critical for the cell death phenotype.
ATM is involved, but not essential for CARF silencing-
induced cell death. As CARF was upregulated by DNA
damage-inducing stress signals, such as treatment with
doxorubicin, etoposide and camptothecin, we considered
whether CARF suppression causes genotoxicity leading to
apoptotic cell death and examined the effect of CARF
suppression on the ATM–ATR pathways, critical regulators
of the DNA damage response. As shown in Figure 4a, b and
c, CARF-silencing was associated with increases in total
and phosphorylated ATM (at serine 1981), as well as gH2AX
in both HeLa and U2OS cells suggesting that CARF
suppression initiated a DNA damage response. However,
total expression of CHK2, a downstream effector of ATM, did
not show any changes and analysis of the phosphorylated
forms of CHK2, including phosphorylation at serine 19,
serines 33/35 and threonine 68, also did not reveal any
alterations between control and CARF-suppressed cells,
suggesting that CARF apoptosis is not critically regulated
by the ATM pathway (Figure 4d). This was further suppor-
ted using ATM-deficient cells, FTYZ5 and AT5 BIVA
(data not shown for the latter). We found that the ATM/
cells underwent cell death following CARF suppression very
similar to ATMþ /þ cells (Figure 4e). Furthermore, cell
death in both ATM/ and ATMþ /þ cells showed cleavage
of caspase 3 (Figure 4f) demonstrating that ATM is not
essential for CARF-silencing-induced apoptosis.
Suppression of the ATR–CHK1 pathway is a critical
factor in CARF-silencing-induced cell death. In contrast
to ATM and CHK2, ATR was suppressed after CARF
inhibition in both HeLa and U2OS cells (Figure 4a), which
was accompanied by decreases in total CHK1 and phospho-
CHK1 (Figure 4d). To verify that the suppression of this
pathway is a critical factor in CARF-inhibition-induced cell
death, GFP-CHK1 was transiently overexpressed (Figure 5a)
and then subjected to CARF suppression. As shown in
Figure 5b, although cell death was still observed in the
control vector cells following CARF suppression, cell viability
was maintained in the cells with CHK1 overexpression.
Further, cyclin B1 and histone H3 (the major markers of MC),
as well as gH2AX, which showed increases in control
CARF-compromised cells (Figures 1c and 5c), were
normalized in the CHK1-overexpressing, CARF-
compromised cells (Figure 5c and d). Immunofluorescent
staining showed that CARF siRNA transfection effectively
decreased CARF expression (Figure 5d). Cyclin B1 was
found predominately in the cytoplasm of cells and gH2AX foci
were very rare in the control cells (Figure 5e and f, 1st and
3rd columns). In the CARF-compromised control vector cells,
nuclear cyclin B1 and gH2AX showed accumulation (Figure
5e and f, 2nd column). In contrast, the CHK1-overexpressing
cells did not accumulate cyclin B1 and gH2AX after CARF
suppression (Figure 5e and f, 4th column). Noticeably, cells
that lacked CHK1 expression (as evidenced by lack of GFP
signal, white arrowheads), accumulated nuclear cyclin B1
and gH2AX after CARF suppression while CHK1-
overexpressing cells did not (yellow arrows). These results
were also seen in HeLa cells (data not shown).
We further confirmed that CHK1 overexpression reverted
the apoptosis in CARF-compromised cells by investigating the
activation of caspases, as well as by TUNEL staining (Figure
5g and h). We observed increased cleavage of caspase 9 in
the control U2OS cells following CARF knockdown, as shown
previously, however, this cleavage was normalized in the
CHK1-overexpressing cells (Figure 5g). Consistent with
apoptosis, caspase 3 activity was substantially increased in
control U2OS, but not in CHK1-overexpressing cells after
CARF knockdown (Figure 5h). TUNEL staining also revealed
increased apoptosis in the control U2OS cells following CARF
knockdown and a reversion of this phenotype in the CHK1-
overexpressing cells (Figure 5i).
In order to determine the mechanism by which CARF
regulates CHK1, we performed reverse-transcription PCR to
observe the transcriptional status of CHK1 following CARF
knockdown. We found that CHK1 was significantly down-
regulated in the CARF-compromised cells, suggesting that
CARF is a transcriptional regulator of CHK1.
Thus, we conclude here that suppression of CARF resulted
in downregulation of the ATR–CHK1 pathway via transcrip-
tional repression of CHK1 expression, leading to MC and
apoptosis, and exogenous upregulation of CHK1 reverted the
cell death phenotype (Figure 6).
CARF targeting causes tumor suppression in vivo. As
described above, siRNA-mediated CARF suppression
induced apoptosis in cultured cancer cells implicating its
antitumor potential. To verify whether the suppression of
CARF is antitumoral in vivo, we used A549 cells (a lung
carcinoma with wildtype p53, RB and ATR–CHK1 pathways)
in a human tumor xenograft nude mouse model. In order to
achieve stable suppression of CARF expression, we used
adenovirus as a carrier. We introduced CARF shRNA
(shCARF) under the control of a U6 promoter in the E3
region of an E1A-mutated and E1B-deleted adenovirus,
Ad-DB7, generating Ad-DB7-shCARF. Relative efficacy of
the virus infection and cytotoxicity were compared with the
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Figure 4 CARF suppression activates the ATM pathway, but it is not required for cell death. Total ATM, total ATR and gH2AX, as well as CARF levels were analyzed
by immunoblotting with densitometric quantitation of representative blots from at least three experiments, in which the CARF-suppressed group is shown as fold change
over control, which was set as 1 (a). Phosphorylated ATM at serine 1981 (b) and gH2AX (c) were detected by immunofluorescent staining, wherein, blue stain denotes
nuclei. The phosphorylated forms of CHK2, including phosphorylation at serine 19, serines 33/35 and threonine 68, total CHK1 and phosphorylated CHK1 were examined
by western blotting (d). ATM þ /þ and null cells were transfected with CARF siRNA, in which apoptosis is shown as rounded, floating cells in the images (e), and cleavage
of procaspase 3 was detected by immunoblotting (f). Actin was used as loading control and Hoechst 33 258 was used for nuclear staining. Graphs are represented as average
mean±S.D.
CARF regulates DNA damage and mitotic catastrophe
CT Cheung et al
595
Cell Death and Differentiation
control vectors in in vitro cytotoxicity assays (Figure 7a). We
found that the CARF-targeting adenovirus evoked a cytotoxic
response in A549 cells even at multiplicities of infection
(MOI) 0.2; it was about threefold more potent than the control
carrier DB7. Oncolytic control and CARF-targeting
adenoviruses were examined for their ability to suppress
the growth of A549 xenografts established in nude mice.
When the subcutaneously implanted A549 tumors reached
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transfected cells, which was considered as 100% (b). Immunoblots for CARF, GFP, gH2AX, histone H3 and cyclin B1 were performed in control and CHK-1 overexpressing
cells following CARF inhibition with densitometric quantitation of representative blots from at least three experiments, in which the CARF-suppressed group is shown as
fold change over control, which was set as 1 (c). Immunofluorescent staining was also performed for CARF, cyclin B1 and gH2AX in methanol/acetone-fixed cells (CARF
siRNA-transfected control and CHK1 overexpressing) (d–f). For characterization of the apoptotic phenotype, caspase activation was examined by immunoblotting (g) and
fluorescence-based assay (h) in control and CHK1-overexpressing cells following CARF knockdown. Further, TUNEL staining was conducted and quantitated by counting a
total of 500–2000 cells from two independent experiments (i). Lastly, using reverse-transcription PCR for CHK1 performed in control and CARF-suppressed cells, we
demonstrated that CHK1 transcripts were reduced following CARF knockdown. The PCR products were quantitated from two independent experiments, and the CARF siRNA
sample is shown as fold change over control. a-Tubulin was used as loading control and Hoechst 33 258 was used for nuclear staining. Graphs are represented as average
mean±S.D.
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approximately 100 mm3 in volume, tumors were randomized
and treated with phosphate-buffered saline (PBS), Ad-DB7 or
Ad-DB7-shCARF thrice daily on alternate days. Daily
observations on tumor volume, body weight and general
activity were continued until the experiment was terminated
at 50 days. As early as 3 days of treatment, there was a
regression in the size of the tumors in the shCARF group
(Figure 7b, gray circles). Although there was a cytotoxic
effect from the adenovirus carrier, beginning from day 20 of
treatment, tumors of the shCARF group continued to regress
while tumors of the Ad-DB7 control group began to enlarge in
size. By day 50, in comparison to the PBS-treated control
tumors (average tumor volume; 692.6 mm3), Ad-DB7 treated
group showedB61% reduction in tumor size (average tumor
volume; 267.9 mm3). The cytotoxic effect was much
more pronounced (average tumor volume 73.3 mm3
implicating B89% reduction in tumor growth) with CARF-
targeting adenoviruses, Ad-DB7-shCARF. Furthermore,
CARF-targeting adenovirus significantly averted mortality
related to large tumor size. Although all the PBS control mice
died by day 35 and 50% of the Ad-DB7 control group died by
the end of the experiment, all the Ad-DB7-shCARF mice
were alive with no or very small tumors by day 50 (Figure 7c).
We observed no marked treatment-related toxicities affecting
feeding, activity or body weight of mice. These data
confirmed that our CARF-targeting strategy caused tumor
suppression in vivo and, hence, shCARF is a potential
antitumor reagent either by itself or in concert with adeno-
oncolytic viruses.
Discussion
We had previously found that CARF, a novel p53-regulatory
protein, can dose-dependently induce senescence (overexpres-
sion) and apoptosis (downregulation).20 In this report, we
elucidated the mechanisms that regulated the apoptotic process
following CARF inhibition. We show here that, CARF is a
pleiotropic protein that not only mediates p53 and its related
pathways, but also synergizes with multiple signaling cascades
including the ATM–ATR, Ras–MAPK and RB pathways
responsible for cell survival and cell death. As shown in Figure 1,
we found that the apoptotic program is, through MC, mediated
by activation of the mitochondrial–internal stress and caspase
pathways including upregulation of Bak (pro-apoptotic protein),
downregulation of Bcl-2 (antiapoptotic protein) and activation of
caspases 9, 7, 2 and 3.
Genome integrity is the basis for proper cell growth,
proliferation and survival, and loss of genome integrity may
result either in cell death or arrest to prevent growth of
abnormal cells or tumorigenesis.21 It has been established
that genotoxic stress or checkpoint abrogation through CHK1
inhibition can lead to MC and caspase-dependent apoptosis
Procaspase 9
Cleaved caspase 9
Actin
U2OS WT
U2OS
+ CHK1
Con.
siRNA
CARF
siRNA
Con.
siRNA
CARF
siRNA
Con.
siRNA
CARF
siRNA
Con.
siRNA
CARF
siRNA
Con.
siRNA
CARF
siRNA
Control
siRNA
CARF
siRNA
CARF
Control CARF siRNA
U2OS
G
FP
H
o
ec
hs
t
TU
NE
L
Control CARF siRNA
U2OS + CHK1
0
1.0
2.0
3.0
4.0
5.0
GFP
GFP-CHK1
TU
NE
L 
po
si
tiv
ity
( f
old
 of
 co
nt
ro
l)
N1
CHK1
0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
Ca
sp
as
e 
ac
tiv
iit
y
(fo
ld 
ov
er
 co
nt
ro
l)
U2OS
CHK1
GAPDH
CH
K1
 e
xp
re
ss
io
n
( f
old
 of
 co
nt
ro
l)
0
0.2
0.4
0.6
0.8
1.0
Figure 5 Continued
CARF regulates DNA damage and mitotic catastrophe
CT Cheung et al
597
Cell Death and Differentiation
for which cyclin B1 accumulation is a biomarker.22,23 We found
that CARF suppression downregulated the essential genome
safeguards, ATR and CHK1, which led to DNA damage as
evidenced by increased gH2AX (Figure 5a and c). This
appeared to be the primary cause of DNA damage
in CARF-compromised cells, as overexpression of CHK1
in CARF-compromised cells reverted not only the cell death
phenotype, but also abolished the induction of gH2AX (Figure 5).
The significance of ATR and CHK1 in maintaining genome
integrity has been shown by other studies, in which exogenous
suppression of this pathway leads to formation of single-
stranded DNA, DNA breaks and telomere instability, and
complete knockout of ATR or CHK1 is embryonic lethal.24,25
CHK1 may also function downstream of ATM, but after CARF
inhibition, ATM was upregulated and activated as evidenced by
phosphorylation at serine 1981, although CHK2 was not
activated and CARF knockdown in ATM deficient cells did not
alter the cell fate (Figures 5 and 6). The data suggest that CARF
knockdown induced genotoxicity and severely stunted the DNA
damage response. As CHK1 inhibitors are currently being
developed as adjuvants to enhance the efficacy of genotoxic
antitumor agents, our results suggest that CARF may also be
useful as a therapeutic reagent.
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Figure 6 Schematic diagram of the hypothetical pathways that lead to
CARF-suppression induced apoptosis. Our results excluded the crucial involvement
of Ras-MAPK and RB–E2F1 pathways and demonstrated that mitotic arrest and
cell death induced by CARF inhibition progresses via the ATR–CHK1 pathway
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Figure 7 CARF suppression in vivo induces tumor regression. A549 cells were
infected with MOI from 0.2–5 of shCARF-carrying adenovirus to determine the
optimal dose (a). Nude mice (n¼ 5–6 per group) were injected with 1 107 A549
cells, and when tumors reached 100 mm3 in volume, either 3 108 plaque forming
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intratumorally three times every 2 days, at which time the tumor size was
also measured (b). Survival of the animals was also recorded as percentage (%)
viability (c). The mice were killed on day 50
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CARF suppression and the subsequent DNA damage also
affected the Ras–MAPK and RB–E2F1 pathways seemingly
to induce cell cycle arrest, but the reconstitution of these
factors following CARF inhibition did not protect the cells
against CARF-silencing-induced apoptosis. The quintessen-
tial MAPK pathway is crucial in organismal development,
having pivotal roles in cell survival, proliferation, differentiation
and death pathways.8 This pathway consists of three major
groups: the ERKs, stress-activated protein kinase/c-Jun NH2-
terminal kinase and p38MAPK. Ras, a key upstream player in
this pathway, can invoke both cellular proliferation, as
observed by neoplastic activity via oncogenic Ras activation
and subsequent MAPK or phosphoinositide 3-kinases (PI3-K)
transduction and cell death. Further, MAPK are known to
participate in the maintenance of G2/M arrest and they are
required for exit from growth arrest and transition through
mitosis.26 In our previous study, we had found that Ras can
induce CARF, and we show here that CARF inhibition
reciprocally decreases Ras, leading to downregulation of the
Ras-mediated MAPK pathway, possibly as a measure to halt
the cell cycle. Nonetheless, using two independent assays
including ERK-overexpressing and HT1080 cells, we found
that the Ras–MAPK pathway is not essential for CARF-
inhibition-induced apoptosis. In contrast, we show that CHK1
levels remained the same in control and CARF-siRNA treated
HT1080 cells (Figure 2e), which suggested that CHK1 has a
role in preventing cell death in these cells.
Similarly, RB–E2F1 pathway, another important pathway in
regulation of cell cycle arrest and apoptosis was not critically
involved in CARF siRNA-involved cell death. Cell cycle pro-
gression requires phosphorylation of RB by cyclin-dependent
kinases and their partner cyclins to free E2F proteins and
subsequent transactivation of a plethora of cell cycle regulat-
ing genes.6 Hypophosphorylated RB binds to and inhibits the
activity of E2F proteins, leading to suppression of a variety of
genes including those required for cell cycle progression.
Further, RB and E2F proteins have been implicated in
regulation of apoptosis, wherein, hypophosphorylated RB
binds to E2F1, leading to growth arrest followed by apopto-
sis.27,28 Proper RB function is required for maintenance of
G2/M arrest following DNA damage and disruption of RB
accelerated G2/M progression in the presence of DNA
damage by elevating E2F activity and the expression of a
mitotic regulatory genes.29 Our results demonstrated that
CARF suppression led to hypophosphorylated RB and
downregulation of E2F1, suggesting that CARF inhibition
may also activate this pathway to bring about growth arrest.
However, although Saos-2 cells, which lack RB, were
resistant to CARF-inhibition induced cell death, restoration
of RB to Saos-2 did not revert the phenotype, which indicated
that RB is not sufficient to revert the apoptosis induced by
CARF suppression. On the other hand, CHK1 expression was
identical between control and CARF siRNA-treated Saos-2
cells (Figure 3c and d), suggesting that in Saos-2, similar to
those in HT1080 cells, the retention of CHK1 levels prevented
the apoptotic phenotype as seen in the other cell lines with
downregulated CHK1.
The data suggested that the primary effect of CARF
suppression is loss of DNA protection and induction of DNA
damage owing to downregulation of the ATR–CHK1 pathway
through transcriptional repression of the CHK1 gene, leading
to induction of mitotic arrest and cell death. We show that
CARF is an essential genome safeguard that critically
regulates the ATR–CHK1 pathway and its inhibition induces
cell death via ATR–CHK1 dysregulation that also involves the
Ras-MAPK, ATM–CHK2 and RB–E2F1 pathways (Figure 6).
These results highlight the pleiotropic effects of CARF as its
knockdown impinges upon multiple pathways and its potential
as a novel therapeutic reagent.
Furthermore, in vivo suppression of tumoral CARF com-
pletely abrogated tumor growth leading to 100% animal
survival, providing evidence that CARF is a strong anticancer
therapeutic target (Figure 7). Our in vivo strategy involved
using oncolytic adenovirus to carry shCARF directly to
tumors, which caused complete tumor regression, and
viability of the animals was preserved as compared with the
vehicle controls. Infection of tumor cells with adenoviruses
induces an immune response which enhances the recognition
of tumor antigens.30 However, a high infective dose may
cause acute cytotoxicity. To circumvent this, generation of
mutant adenoviruses with enhanced specificity to tumor cells
to decrease side effects and increase efficacy has been
developed. Adenovirus carrying the E1B7 deletion (Ad-DB7)
has been shown to markedly increase oncolysis and
apoptosis, potentiating its development as a novel anticancer
therapy, but its tumor-targeting effect is still considered mild,
thus, it may be more effective as an adjuvant treatment.31
Previously, adenovirus with E1 deletions exhibited enhanced
efficacy and tumorilytic activities when administered in conju-
nction with radiotherapy or chemotherapeutic drugs.32,33
Alternatively, using the mutant adenovirus as anticancer gene
carriers had also demonstrated increased oncolytic efficacy.34
Thus, in our study, we utilized Ad-DB7 as a gene carrier for
shCARF. Although Ad-DB7 alone showed a moderate degree
of oncolysis and inhibition of tumor growth, by 21 days of
treatment, tumor growth resumed followed by animal mortality
presumably owing to the increase in tumor burden (Figure 7).
In contrast, Ad-DB7-shCARF showed tumor regression
throughout the experimental period and complete preserva-
tion of animal viability. This demonstrated that CARF
suppression might be a safe and effective antitumor reagent
in conjunction with oncolytic adenovirus administration with no
observed side effects such as cytotoxicity.
Materials and Methods
Cell culture. All the cell lines were obtained from the America Type Culture
Collection (Manassas, VA, USA) unless otherwise specified. The HCT116 human
colon cancer cell lines (p53/ and p53þ /þ ) were a gift from Dr. Bert Vogelstein
(The Johns Hopkins Kimmel Cancer Center, Baltimore, MD, USA) and the
ATM-deficient cells FT/pEBS7 (hereby referred to as FT vector or FTV) and control
cell line FT/pEBS7-YZ5 (FTYZ5) were derived from the AT22IJE-T line, an
immortalized fibroblast line, and generously provided by Dr. KumKum Khanna
(Queensland Institute of Medical Research, Herston, Australia).35 All the cell lines
were cultured in Dulbecco’s modified Eagle’s minimal essential medium (Invitrogen,
Carlsbad, CA, USA) supplemented with 5–10% fetal bovine serum (Invitrogen) at
371C with 95% O2 and 5% CO2 in a humidified chamber.
CARF siRNA and plasmid transfections. The synthesis and sequences
of CARF siRNAs are described elsewhere.2 Briefly, for annealing of siRNAs, 20 mM
of each control or target sense and antisense strand were incubated in annealing
buffer (100 mM potassium acetate, 30 mM HEPES-KOH at pH 7.4 and 2 mM
magnesium acetate) for 1 min at 901C followed by 1 h at 371C. Transfection of
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siRNA duplexes was carried out using Oligofectamine reagent (Invitrogen) as
previously described. For plasmid transfections, the cDNA encoding full-length
ERK1 tagged with GFP (Addgene, Cambridge, MA, USA; plasmid #14 747)
generously provided by Dr. Rony Seger from the Weizmann Institute of Science
(Rehouot, Israel), RB tagged with HA (Addgene plasmid #10 720) provided by
Dr. William Sellers from the Dana Farber Cancer Institute (Boston, MA, USA), and
GFP-tagged CHK1 which was a gift from Dr. Aziz Sancar from the University of
North Carolina School of Medicine (Addgene plasmid #22 888) were transiently
transfected into cells using Fugene 6 (Roche, Basel, Switzerland) following the
manufacturer’s protocol. Briefly, cells were plated into a 6-well plate, 2 mg of each
vector was transfected into cells at a ratio of 6 : 1 of transfection reagent to DNA in
antibiotic-free media with 10% fetal bovine serum, and after 48 h, cells were washed
and subsequently transfected with CARF siRNA.
TUNEL staining. TUNEL staining was performed as before.3 Briefly, cells were
plated onto coverslips, transfected with CARF or control siRNA, and then subjected
to TUNEL staining using the DeadEnd Fluorometric TUNEL System (Promega,
Madison, WI, USA) or the ApopTag Red In Situ Apoptosis Detection (Millipore,
Billerica, MA, USA) kits as described previously.
Cell culture treatments. All chemical reagents were purchased from Sigma-
Aldrich (St. Louis, MO, USA) unless otherwise specified. Cells were treated
with 20mM each of wortmannin (PI3K/Akt inhibitor), PD98059 (MEK inhibitor) and
SB203580 (p38MAK inhibitor) for inhibition of the various Ras-associated pathways
and with 50mM of zVAD.fmk for inhibition of caspases. The treatments were
performed simultaneously with CARF siRNA transfection complexes to the cells,
using dimethyl sulfoxide as the vehicle control and cells were harvested after 48 h.
All the experiments were performed in triplicate at least three times.
Western blot analysis. The protein samples (10–20mg) were harvested
using Nonidet-P40 lysis buffer (20 mM Tris, 100 mM EDTA, 100 mM EGTA, 100 mM
PMSF, 150 mM NaCl and 1% NP-40) or RIPA buffer (Thermo Scientific Corp.,
Waltham, MA, USA), separated in SDS-polyacrylamide gels, and electroblotted
onto PVDF membranes (Millipore) using a semidry transfer blotter (Biometra,
Tokyo, Japan). Immunoblotting was performed with antibodies against: Bak, Bax,
caspase 3,7, 8 and caspase 9, ATM, ATR, E2F1, p21WAF1, GFP and HA purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA); Bcl-xL, Bcl-2, total CHK1,
phospho-CHK1, total CHK2, phospho-CHK2, total RB and phospho-RB from Cell
Signaling (Danvers, MA, USA); total ERK1/2 from Abcam (Cambridge, MA, USA);
and Ras, phospho-ERK1/2, cyclin B1, histone H3 and caspase 2 obtained from
BD Biosciences (Franklin Lakes, NJ, USA). The monoclonal anti-actin (Millipore),
monoclonal anti-atubulin (Sigma-Aldrich), anti-phospho1981 ATM (Genetex, Irvine,
CA, USA), anti-gH2AX (Millipore), anti-FADD (MBL, Nagoya, Japan) and polyclonal
anti-CARF2 antibodies were also used. The immunoblots were incubated with
horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit antibodies (Santa
Cruz Biotechnology) and detected using ECL substrate (Amersham Pharmacia
Biotech/GE Healthcare, Piscataway, NJ, USA). Densitometric quantitation of the
representative immunoblots was carried out using the ImageJ software (National
Institute of Health). The data are shown as relative units wherein, control siRNA
bands are given a value of 1 and CARF siRNA bands are calculated as fold change
over control. All the experiments were performed in triplicate at least three times.
Immunofluorescent staining. For immunocytostaining, cells were grown
on glass coverslips or trypsinized after treatments and cytospun onto coated glass
slides using the Cytospin 4 instrument (Thermo Scientific), and then fixed with
equal volume of cold methanol and acetone for 10 min, followed by permeabilization
using PBS with 2% Triton 0X-100 for 10 min at room temperature. The cells were
incubated with anti-phospho1981 ATM, anti-cyclin B1, anti-gH2AX and/or anti-
CARF antibodies at room temperature for 1 h or at 41C overnight, probed with Alexa
Fluor-conjugated secondary antibodies (Molecular Probes, Invitrogen) and finally
counterstained with Hoechst 33 258 (Sigma-Aldrich). The slides were viewed using
a Zeiss Axioplan 2 microscope and images were taken using a AxioCam HRc
camera (Carl Zeiss, Tokyo, Japan).
Caspase 3 activity assay. Caspase 3 activity was measured using the BD
Biosciences kit as per the manufacturer’s instructions. Briefly, cells were treated with
control or CARF siRNA and 48 h following transfection, cells were lysed and
subjected to the assay. Fluorescence was measured using a plate reader with an
excitation wavelength of 380 nm and an emission wavelength range of 420–460 nm.
The fluorescence intensity is plotted as a ratio of fold change over control siRNA.
Cell viability assay. Cells were trypsinized, stained with trypan blue and
counted using a hemocytometer. The data is shown as percentage of control cells,
which is represented as 100%. All the experiments were performed in triplicate at
least three times.
Reverse-transcription PCR. Total RNA was isolated from control and
CARF-siRNA transfected cells at 48 h using the Rneasy Mini Kit from Qiagen
(Germantown, MD, USA). The primer sequences were as follows: (sense) 50 GATG
CAGACAAATCTTATCAATGC 30 and (antisense) 50 AGTTTGCAGGACAGGAT
AATCTTC 30 for CHK1 and GAPDH (glyceraldehyde 3-phosphate dehydrogenase)
was used as an internal control. The PCR cycle included an initial 10 min
denaturation step at 951C followed by 25 cycles of 951C for 45 s, 60 1C for 45 s and
72 1C for 45 s, with a final annealing step at 72 1C for 10 min. The PCR products
were separated in 0.8% agarose gel and quantitated using the ImageJ program.
The CHK1 product was normalized to GAPDH and the CARF-compromised group
was plotted as fold change over control, which was set as 1. All samples were
performed in triplicate from at least two independent experiments.
Generation of CARF-carrying adenovirus (Ad-DB7-shC
ARF). Adenoviruses were chosen to carry shRNA against CARF as an in vivo
carrier because of their enhanced oncolytic ability and safety.33 We introduced
shCARF, the sequences of which are identical to the CARF siRNA described above,
under the control of an U6 promoter in the E3 region of an E1A-mutated and
E1B-deleted adenovirus, Ad-DB7, generating Ad-DB7-shCARF.
Cytopathic effect assay. A549 lung adenocarcinoma cells were plated into
48-well plates at approximately 30–70% confluency and then infected with Ad-DE1,
Ad-DB7 or Ad-DB7-shCARF at an MOI of 0.2–5. After 5–7 days of incubation at
371C, the plates were gently washed to remove non-viable cells and the living cells
on the plate were then stained with 0.5% crystal violet in 50% methanol.
Antitumor effects in human xenograft model. Human lung tumor
xenografts were established in 6-to-8-week-old male athymic nu/nu mice (Charles
River Japan Inc., Yokohama, Japan). Mice were subcutaneously implanted with
1 107 A549 human lung cancer cells in the abdominal region. When tumors grew
to about 100 mm3 in volume, they were injected thrice daily every 2 days with either
3 108 plaque forming unit of Ad-DB7 or Ad-DB7-shCARF. Tumor growth was
monitored thrice weekly by measuring the length and width of the tumor until the end
of the study. Tumor volume was estimated on the basis of the following formula:
volume¼ 0.523Lw2 (L, length and w, width). All the animal studies were conducted
at the Yonsei University College of Medicine, an Association for Assessment and
Accreditation of Laboratory Animal Care-accredited animal facility, according to
institutional regulations.
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